Phase Iii Open Label Clinical Study

Neurotech embarks on ground-breaking ASD trials

Finfeed Archived May 05, 2021

Neurotech International (ASX: NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with ASD.